Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Spyre Therapeutics, Inc. (SYRE)

96.56 -2.40 (-2.43%)
At close: 4:00:00 PM EDT
96.45 -0.11 (-0.11%)
After hours: 4:00:10 PM EDT
Trade SYRE on Coinbase
Chart Range Bar
Loading chart for SYRE
  • Previous Close 98.96
  • Open 96.78
  • Bid 69.12 x 200
  • Ask 122.02 x 200
  • Day's Range 94.68 - 98.96
  • 52 Week Range 21.15 - 110.18
  • Volume 658,464
  • Avg. Volume 1,207,410
  • Market Cap (intraday) 9.024B
  • Beta (5Y Monthly) 3.11
  • PE Ratio (TTM) --
  • EPS (TTM) -1.92
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 122.33
  • Zacks Rating Neutral

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

www.spyre.com

125

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SYRE
194.75%
S&P 500 (^GSPC)
10.73%

1-Year Return

SYRE
298.02%
S&P 500 (^GSPC)
11.11%

3-Year Return

SYRE
726.71%
S&P 500 (^GSPC)
81.91%

5-Year Return

SYRE
47.23%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -36.2M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-60M
-40M
-20M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

110.00
122.33 Average
96.56 Current
130.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/19/2026
Analyst BTIG
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 121 -> 121

Statistics

View More

Valuation Measures

Annual
As of 10/28/2026
  • Market Cap

    9.25B

  • Enterprise Value

    8.25B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    9.20

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -19.81%

  • Return on Equity (ttm)

    -22.98%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -150.21M

  • Diluted EPS (ttm)

    -1.92

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.15B

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -89.05M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

96.56 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: